RxDoctor Payments Data

Grant Scarborough, MD

Internal Medicine · Columbus, GANPI 1790736262

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 77 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$267
  • Pfizer$165
  • Novo Nordisk$157
  • Lilly USA, LLC$149
  • Sanofi-aventis U.S. LLC$136
  • Johnson & Johnson$70
  • plus $339 from 11 others

What the payments were for

  • Food & beverage$1,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,284 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$70,573
Medicare patients
273
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$118,144
EliquisApixaban96$102,200
FarxigaDapagliflozin Propanediol83$88,213
JardianceEmpagliflozin66$82,040
MounjaroTirzepatide53$57,188
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$52,978
JanuviaSitagliptin Phosphate51$44,873
XareltoRivaroxaban19$29,522
EntrestoSacubitril/Valsartan30$27,825
VraylarCariprazine Hcl14$22,309
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,601
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$14,701
SymbicortBudesonide/Formoterol Fumarate37$11,162
Combivent RespimatIpratropium/Albuterol Sulfate11$10,651
Breo ElliptaFluticasone/Vilanterol25$10,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$157$118,14495 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$56$115,976139 claims
PfizerEliquis$165$102,20096 claims
Boehringer IngelheimJardiance, Combivent Respimat$67$92,69077 claims
GSKTrelegy Ellipta, Breo Ellipta$14$63,39177 claims
Lilly USA, LLCMounjaro$149$57,18853 claims
MerckJanuvia$15$44,87351 claims
Johnson & JohnsonXarelto$70$29,52219 claims
AbbVieVraylar, Synthroid$267$23,67230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →